---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-276093"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-06-18T21:13:03+00:00"
generated_at: "2026-06-18T21:14:13.936025+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Faeth Therapeutics enters $150M ATM equity facility; Series B preferred converts to common

## Summary
- Entered Sales Agreement with TD Securities for at-the-market offering of common stock up to $150M.
- Agent TD Securities receives up to 3% commission; shares sold at market prices from time to time.
- Series B Non-Voting Convertible Preferred (24,435.6 shares) automatically converted into 24,435,594 common shares on June 15.
- Post-conversion, common shares outstanding increase to 25,778,754 as of June 15, 2026.

## SEC filing metadata
- accession: 0001193125-26-276093
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-06-18T21:13:03+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/0001193125-26-276093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/d82589d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-276093
- JSON: https://secwatch.observer/filing/0001193125-26-276093.json
- Plain text: https://secwatch.observer/filing/0001193125-26-276093.txt

## Key facts
- Material Agreements
  Sensei Biotherapeutics, Inc. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $150,000,000 (effective 2026-06-18).
  - Action: entry
  - Agreement: atm program
  - Counterparty: TD Securities (USA) LLC
  - Value: up to $150,000,000
  - Effective: 2026-06-18
  source text: On June 18, 2026, Faeth Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/0001193125-26-276093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.